Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia [6]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 520-523

  Houston, John P ^a   Adams, David H ^a   Kirkwood, Sandra C ^a   Farmen, Mark ^a   Downing, Anncatherine M ^a   Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; DOPAMINE; HALOPERIDOL; OLANZAPINE; SEROTONIN;

DECISION MAKING; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA POLYMORPHISM; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; LETTER; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOMETRICS; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; REMISSION INDUCTION; SCHIZOPHRENIA;

EID: 34548677283     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814f4d82     Document Type: Letter

References (13)

1. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14: 229-234.
2. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25:157-171.
3. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
4. Jurinke C, van den Boom D, Cantor CR, et al. Automated genotyping using the DNA MassArray technology. Methods Mol Biol. 2002;187:179-192.
5. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
6. Reynolds GP, Arranz B, Templeman LA, et al. Effect of the 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;16:1826-1829.
7. Ellingrod VL, Lund BC, Miller D, et al. 5-HT2A receptor promoter polymorphism, -1438 G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol Bull. 2003;37:109-112.
8. Yu YW, Tsai SJ, Lin CH, et al. Serotonin-6 receptor variation (C267T) and clinical response to clozapine. Neuroreport. 1999;10: 1231-1233.
9. Serretti A, Artioli P. From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology. 2004;174:490-503.
10. Cavalli-Sforza LL, Bodmer WF. The Genetics of Human Populations. New York: Dover Publications Inc; 1999:57.
11. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med. 2006;38: 82-94.
12. Cohrs S, Röher C, Jordan W, et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology. 2006;185:11-18.
13. Licinio J, Wong ML. Pharmacogenomics in psychiatry: clinical issues to be considered. Mol Psychiatry. 2005;10:615.